Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

New York, New York 10065


The purpose of this study is to learn more about how a new study agent works inside the body. This study agent is a protein called 68Ga-F(ab')2-trastuzumab fragments (HERScan). This is a radioactive tracer that was developed at MSKCC to target the HER2 protein on cancer cells. By giving this tracer to patients whose cancers have the HER2 protein, we hope to be able to see the level of HER2 on the cancer cells using PET scanning.


Inclusion Criteria: - Registered patient at MSKCC - Age ≥ or = to 18 years - Patients with invasive solid tumors. - Measurable or evaluable disease - Patients must have had routine disease staging studies with CT scan, FDG PET/CT scan, bone scan and/or MRI within 8 weeks of enrollment onto this trial - Karnofsky Performance Score ≥ or = to 60 - Signed informed consent Exclusion Criteria: - Claustrophobia/pain or any other disability leading to inability to lie still for the duration of the scanning procedure. - Pregnancy Test to be performed on female patients of childbearing potential within 24hrs before administration of radioactive material. - Patients with known sensitivity or contraindication to Herceptin. - Inability to provide written informed consent.



Primary Contact:

Principal Investigator
Jorge Carrasquillo, MD
Memorial Sloan Kettering Cancer Center

Backup Contact:


Location Contact:

New York, New York 10065
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.